Description
Cagrilintide is a long-acting analogue of amylin, a hormone naturally co-secreted with insulin by pancreatic beta cells.
Amylin is involved in post-meal signalling, including satiety, gastric emptying and glucagon regulation. Cagrilintide has been developed to activate amylin-related pathways for longer periods, and research has focused particularly on appetite regulation, energy intake, body-weight control and broader metabolic effects.
In plain English: researchers are interested in cagrilintide because it may help people feel fuller for longer, reduce appetite and food intake, and support reductions in body weight by mimicking some of the effects of the natural hormone amylin.
Clinical studies have investigated cagrilintide both on its own and in combination with semaglutide. Human trials and recent analyses have reported meaningful reductions in body weight, while ongoing research continues to assess longer-term effectiveness, tolerability and its role in metabolic and weight-management research.
Supplied by Black Knight Peptides for laboratory and research purposes only.
Not for human consumption.
